NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock.

Several other equities research analysts have also commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $36.75.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ:NRXP opened at $1.80 on Tuesday. The firm’s 50 day simple moving average is $2.21 and its 200-day simple moving average is $2.57. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84. The firm has a market cap of $53.28 million, a PE ratio of -0.77 and a beta of 1.92.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. Equities research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the third quarter worth $39,000. One Wealth Management Investment & Advisory Services LLC lifted its stake in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the period. AdvisorShares Investments LLC grew its holdings in shares of NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.